Physician profile
Michael K Smith
NPI 1033102413
$3,195.71
in general payments reported to CMS, 2019-2025
26 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $195 · 2021: $532 · 2022: $431 · 2023: $412 · 2024: $489 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230 · Education: $13.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.91 |
| Education | $13.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $609.38 | 2021-2025 | Symplicity G3, Micra |
| Novartis Pharmaceuticals Corporation | $522.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $352.97 | 2020-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $300.64 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $225.16 | 2019-2024 | Lifevest |
| Medtronic Vascular, INC. | $215.35 | 2019-2020 | |
| Recor Medical INC | $184.31 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $167.98 | 2019-2024 | Repatha |
| Amarin Pharma, INC. | $146.19 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $92.10 | 2022-2024 | |
| Irhythm Technologies, INC. | $60.45 | 2023 | Zio Xt Patch |
| Pfizer INC. | $48.95 | 2023-2024 | |
| Boston Scientific Corporation | $32.02 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $25.44 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $24.40 | 2024 | Opsumit, Uptravi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $20.95 | 2022 | |
| United Therapeutics Corporation | $20.72 | 2019 | |
| Esperion Therapeutics, INC. | $19.87 | 2021 | |
| Daiichi Sankyo INC. | $19.32 | 2023 | Injectafer |
| Philips North America LLC | $16.95 | 2022 | |
| Melinta Therapeutics, LLC | $16.41 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Kiniksa Pharmaceuticals, LTD. | $16.19 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $16.05 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $15.90 | 2023 | |
| Arbor Pharmaceuticals, INC. | $13.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.